Genentech extends Rituxan PML warning to all uses
This article was originally published in Scrip
Executive Summary
All patients treated with Rituxan (rituximab), regardless of disease, should be monitored for development of progressive multifocal leucoencephalopathy (PML), Genentechsaid.